Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-03-29
2011-03-29
McGarry, Sean R (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C536S023100, C536S024100, C536S024500
Reexamination Certificate
active
07915231
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for treatment of diseases associated with expression of C-reactive protein are provided.
REFERENCES:
patent: 5582979 (1996-12-01), Weber
patent: 5783179 (1998-07-01), Nestor, Jr. et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6764826 (2004-07-01), Yeh et al.
patent: 6770461 (2004-08-01), Carulli et al.
patent: 6964950 (2005-11-01), Crooke et al.
patent: 7250496 (2007-07-01), Bentwich et al.
patent: 7326693 (2008-02-01), Crooke et al.
patent: 7425545 (2008-09-01), Crooke et al.
patent: 7491815 (2009-02-01), Crooke et al.
patent: 2002/0142283 (2002-10-01), Yeh et al.
patent: 2003/0207834 (2003-11-01), Dale et al.
patent: 2004/0241651 (2004-12-01), Olek et al.
patent: 2005/0014257 (2005-01-01), Crooke et al.
patent: 2006/0024727 (2006-02-01), Crooke et al.
patent: WO 96/06624 (1996-03-01), None
patent: WO 99/00418 (1999-01-01), None
patent: WO 00/11207 (2000-03-01), None
patent: WO 03/010284 (2003-02-01), None
Random Primer 24, New England Biolabs, 1998/99 New England Biolabs catalog, cover page, p. 121 and p. 284.
Supplemental European Search Report issued Mar. 17, 2005 for European Patent Application No. 02753388.4-2403, which corresponds to U.S. Appl. No. 11/211,803.
International Search Report dated Jul. 3, 2003 for WO 03/010284, which corresponds to U.S. Appl. No. 11/211,803.
International Preliminary Examination Report dated Sep. 9, 2004 for WO 03/010284, which corresponds to U.S. Appl. No. 11/211,803.
International Search Report dated Jun. 15, 2006 for PCT Application No. PCT/US2004/015576, which corresponds to U.S. Appl. No. 10/858,500.
International Preliminary Report on Patentability dated Apr. 10, 2006 for PCT Application No. PCT/US2004/015576, which corresponds to U.S. Appl. No. 10/858,500.
Supplementary European Search Report dated Dec. 19, 2007 for European Application No. 04752571.2- 2405, which corresponds to U.S. Appl. No. 10/858,500.
Agrawal, SudhirTIBTECH, Oct. 1996 14(376-387).
Arici etal.,“End-stage renal disease,atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link?”,Kidney Intl. 2001 59:407-414.
Bárány P., “Inflammation, serum C-reactiveprotein, and erythropoietin resistance”,Nephrol. Dial Transplant2001 16:224-227.
Bennett et al., “Antisense oligonucleotides as a tool for gene functionalization and target validation”,Biochem. Biophys. Acta1999 1489(1):19-30.
Branch, AndreaTIBS 23, Feb. 1998 45-50.
Gabay et al., “Acute-Phase Proteins and Other Systemic Responses to Inflammation”,New England J. of Medicine1999 448-454.
Highton et al., “The Presence and Possible Significance of C-Reactive Protein in Rheumatoid Inflammation”,J. Rheumatology1985 871-875.
Hulthe et al., “Relationship between C-reactive protein and intima-media thickness in the carotid and femoral arteries and to antibodies against oxidized low-density lipoprotein in healthy men: The Atherosclerosis and Insulin Resistance (AIR) study”,Clinical Science2001 100:371-378.
Jen, et al.,Stem Cells, 2000 18:307-319.
Lagrand et al., “C-Reactive Protein as a Cardiovascular Risk Factor More Than an Epiphenomenon?”,CRP and Cardiovascular Disease1999 96:102.
Lei et al., “Genomic DNA Sequence for Human C-reactive Protein”,J. Biol. Chem.1985 260(24):13377-13383.
Morrow et al., “C-Reactive Protein, Inflammation, and Coronary Risk”,Med. Clinics of North America2000 84(1):149-161.
Ridker et al., “Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events”,N. Engl. J. Med.2001 344(6):1959-1965.
Ridker et al., “Rapid Reduction in C-Reactive Protein with Cerivastatin Among 785 Patients with Primary Hypercholesterolemia”,Circulation2001 1191-1193.
Ruuskanen et al., “C-reactive protein in respiratory virus infections”,J. Pediatrics1985 97-100.
Szalai et al., “C-Reactive Protein Structural Biology, Gene Expression, and Host Defense Function”,Immunologic Research1997 16/2:127-136.
Weintraub, Harold M.Scientific American, 40-46 , Jan. 1990.
Westhuyzen et al., “Review: Biology and Relevance of C-Reactive Protein in Cardiovascular and Renal Disease”,Annals of Clinical&Laboratory Science2000 30(2):133-143.
Woo, et al., “Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component”,J. Biol Chem. 1985 260(24):13384-13388.
Yudkin et al., “Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?”,Atherosclerosis2000 148:209-214.
Skerra et al., “Phosphorothioate primers improve the amplification of DNA sequences by DNA polymerases with proofreading activity”,Nucleic Acids Research(1992) 20(14):3551-3554.
Verma et al., “Modified Oligonucleotides: Synthesis and Strategy for Users” Annu. Rev. Biochem. (1998) 67:99-134.
USPTO Office Action for U.S. Appl. No. 11/211,803 dated Nov. 1, 2007.
USPTO Notice of Allowance for U.S. Appl. No. 11/211,803 dated Oct. 10, 2008.
USPTO Notice of Allowance for U.S. Appl. No. 10/483,424 dated Sep. 14, 2007.
PCT International Search Report for PCT Application No. PCT/US02/22656 dated Apr. 7, 2003.
PCT International Written Opinion for PCT/US02/22656 dated Oct. 7, 2003 (WO 03/010284).
PCT International Search Report for PCT Application No. PCT/US2004/015576 dated Mar. 14, 2006 (WO 2005/005599).
USPTO Office Action for U.S. Appl. No. 11/969,208 dated Jan. 25, 2010.
Crooke Rosanne M.
Graham Mark J.
ISIS Pharmaceuticals Inc.
Jones Day
McGarry Sean R
LandOfFree
Antisense modulation of C-reactive protein expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of C-reactive protein expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of C-reactive protein expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2713825